High YY1 expression associated with a worse outcome of therapy with anti-CTLA-4 in skin melanoma (Van Allen, 2015 dataset) [44], but was related to better anti-PD-L1 therapy outcomes in metastatic urinary bladder cancer (Mariathasan, 2018 dataset) [45]. Here, CTLA4 is linked to cutaneous melanoma.